Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Non-small Cell Lung Cancer (NSCLC)
and you are
over 18
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

The purpose of this study is to determine the safety, tolerability, feasibility and preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as single agent or in combination with PDR001 (programmed cell death 1 receptor antibody (PD-1 Ab)) to NSCLC patients.

Provided treatments

  • Drug: PBF-509_80 mg
  • Drug: PBF-509_160 mg
  • Drug: PBF-509_320 mg
  • Drug: PBF-509_640 mg
  • Drug: Combo PBF-509 (160 mg) + PDR001
  • Drug: Combo PBF-509 (320 mg) + PDR001
  • Drug: Combo PBF-509 (640 mg) + PDR001
  • Drug: RP2D (PBF-509+PDR001)_immuno naïve
  • Drug: Experimental: RP2D (PBF-509+PDR001)_immuno treated
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02403193. The sponsor of the trial is Palobiofarma SL and it is looking for 92 volunteers for the current phase.
Official trial title:
Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC